Stock Price & Analysis

Based on the provided data and recent market activity, here's a comprehensive analysis of ARGX stock:

Technical Analysis

The stock is currently showing mixed technical signals:

• Trading at $409.52 (as of Feb 23), up from recent support level around $380
• RSI-14 at 49.33 indicates neutral momentum
• MACD shows bearish divergence with -1.95 histogram value
• Currently trading between Fibonacci support at $634.72 and resistance at $656.37

Fundamental Strength

• Strong revenue growth: Revenue increased from $410.7M (2022) to $1.22B (2023)
• Improving profitability: Net loss decreased from -$709.6M (2022) to -$295.1M (2023)
• Solid balance sheet with:
  • Current ratio of 9.75x
  • Low debt-to-equity of 0.49%
  • Cash position of $4.1B

Recent Developments & Catalysts

• Analyst consensus remains bullish:
  • JMP Securities maintains Buy rating with $696 target
  • Goldman Sachs maintains Buy rating with €774 target
• Strong Q4 2023 preliminary revenue of $737M, beating consensus of $627.99M
• Company guided FY2024 revenue of $2.2B, above consensus of $2.01B

Recommendation

SELL at current levels based on:

1. Technical indicators showing bearish divergence
2. Stock trading near resistance levels
3. Recent strong rally may have priced in positive developments
4. Consider re-entering around $380-390 support zone

Based on the available data and market analysis, here is the price prediction for ARGX stock in 2025:

ARGX is expected to reach $665-670 by end of 2025, representing approximately 8-9% upside from current levels, driven by continued strong growth of VYVGART sales and potential expansion into new indications. The company's robust Q3 2024 performance with 74% year-over-year revenue growth and successful launch of VYVGART Hytrulo in CIDP supports this outlook.

The technical analysis shows the stock is currently trading around $648, with key resistance at $673.88 and support at $617.21. The RSI at 49.33 indicates neutral momentum, suggesting room for upside potential.

The S1 support level for ARGX Stock is $625.87 ,The R1 resistant level for ARGX Stock is $649.6.

As of the end of day on 2025-02-26, the price of ARGX Stock was $625.44.

The target price for ARGX Stock according to analyst rating is 720.10, with the highest price target at 813.00 and the lowest at 600.00. Analysts have a Strong Buy rating on ARGX Stock overall.

The market cap of ARGX is $38.0B.

Based on the provided data and recent analyst reports, here's a concise analysis of ARGX's valuation:

Technical Analysis

The stock is currently trading at $648.21 in pre-market, showing signs of consolidation near its key Fibonacci pivot level of $645.54. RSI-14 at 49.33 indicates neutral momentum, while the stock trades between its SMA-5 ($642.10) and SMA-10 ($644.01).

Valuation Assessment

The stock appears overvalued based on several key factors:

1. Price-to-Sales (P/S) ratio has significantly decreased from 50.16x in FY2022 to 17.74x in FY2023, but still remains elevated compared to industry standards.

2. Net margin improved from -172.76% to -24.06% year-over-year, showing operational improvement but still indicating unprofitability.

Recent Analyst Views

• JMP Securities maintains a Buy rating with a $696 price target
• Goldman Sachs holds a Buy rating with a $774 target

Key Concerns

• Still operating at a loss with negative EPS of -$5.16 for FY2023
• High valuation multiples despite improving fundamentals
• Significant cash burn rate, though balanced by strong cash position

The stock appears overvalued at current levels considering its negative earnings, high P/S ratio, and premium valuation compared to peers. While showing improving operational metrics and strong analyst support, the current price level may not fully account for execution risks and path to profitability.

argenx SE, formerly arGEN X BV, is the Netherlands-based biopharmaceutical company. It creates and develops a pipeline of differentiated antibody therapeutics using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes: ARGX-110, an antibody for heme malignancies and solid tumors, which modulates functions of tumor such as cell proliferation and survival; ARGX-111, an antagonist of c-Met, a receptor tyrosine kinase involved in cell proliferation, angiogenesis and metastasis in multiple solid tumors; ARGX-112, an antigen which targets atopic dermatitis by neutralization of IL-20 and IL-22 (interleukin) mediated signaling through blockade of their common receptor, among others.

Based on analyst consensus and market data, ARGX stock is projected to reach $701.18 by early 2025, representing a potential 8% upside from current levels of $648.21. The bullish outlook is supported by strong revenue growth of 96.06% and successful commercialization of VYVGART in multiple indications. The company's robust pipeline and global expansion plans could drive further upside to $770 in an optimistic scenario.

ARGX has a total of 1148 employees.